Middle East and Africa Multiplexed Diagnostics Market Report and Forecast 2024-2032

The global multiplexed diagnostics market was valued at USD 12.9 billion in 2023, with the Middle East and Africa holding a significant market share. The market is driven by the growing demand for multiplexed assays in clinical diagnostics. It is expected to grow at a CAGR of 15.2% during the forecast period of 2024-2032, with the values likely to attain USD 46.2 billion by 2032.

Middle East and Africa Multiplexed Diagnostics Market Outlook

• The market share is influenced by the rising expansion efforts of the key market players in the emerging economies. In March 2022, a leading manufacturer of digital PCR (dPCR) diagnostics Stilla Technologies signed deals with multiple distributors including Alliance Global in the Gulf and Africa, among others, to expand its reach into the Middle East and Africa region.
• One of the major Middle East and Africa multiplexed diagnostics market trends is the rise in regulatory approval of advanced multiplexed tests. For instance, in February 2023, BGI Genomics’ multiplex bacterial resistance genes detection kit and multiplex nucleic acid kit for respiratory pathogens received market authorization from the Saudi Food & Drug Authority (SFDA).
• The increased application of multiplexed assays in clinical diagnostics and infectious disease surveillance is expected to augment the market demand in the region.

Middle East and Africa Multiplexed Diagnostics Market Analysis

Multiplexed diagnostics allows the simultaneous detection and analysis of nucleic acids, proteins, or other biomolecules in a single test. These techniques can detect several targets from a single sample resulting in reduced sample volume and faster results. Multiplexed diagnostics are increasingly used in clinical diagnostics and infectious disease surveillance to facilitate early disease detection and monitoring. The rising adoption of these advanced assays in healthcare settings to improve diagnostic workflows and reduce turnaround times is expected to significantly contribute to the Middle East and Africa multiplexed diagnostics market growth.

The market is impacted by the presence of a favourable regulatory environment which facilitates the introduction of innovative multiplexed diagnostic products in the region. In February 2023, BGI Genomics, a global provider of genetic tests and sequencing services, announced that its PM Easy Lab products including multiplex bacterial resistance genes detection kit and multiplex nucleic acid kit for respiratory pathogens have received market authorization from the Saudi Food & Drug Authority (SFDA). The market access to these multiplexed tests in Saudi Arabia is likely to advance clinical diagnosis and encourage the informed use of antibiotics, which is poised to augment the Middle East and Africa multiplexed diagnostics market demand.

The market is also influenced by the rising expansion efforts of the key market players. This growing market penetration increases the availability and accessibility of multiplexed diagnostic products and services in these emerging economies, thereby boosting the market share. For instance, in March 2022, a leading biotechnology company Stilla Technologies signed deals with multiple distributors including Alliance Global in the Gulf and Africa, among others, to expand its reach into the Middle East and Africa region. The agreement offered distribution rights to Stilla’s product portfolio such as the six-color naica system, a next-generation multiplexing digital polymerase chain reaction (PCR) platform, to the partnering companies. Such developments are anticipated to accelerate the market growth by fuelling the adoption of multiplexed diagnostics in clinical laboratories.

Middle East and Africa Multiplexed Diagnostics Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

Market Breakup by Product Type

• Reagents and Consumables
• Instruments
• Others

Market Breakup by Application

• Disease Diagnostics
• Drug Development
• Molecular Diagnostics
• Others

Market Breakup by Technology

• Low Density Multiplexed Assays
• Medium Density Multiplexed Assays
• High Density Multiplexed Assays
• Very High Density Multiplexed Assays
• Next-Generation Sequencing Assays
• Others

Market Breakup by End User

• Hospitals
• Clinical Laboratories
• Academic and Research Institutes
• Diagnostic Centers
• Others

Market Breakup by Country

• Saudi Arabia
• United Arab Emirates
• Nigeria
• South Africa
• Others

Leading Players in the Middle East and Africa Multiplexed Diagnostics Market

The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Thermo Fisher Scientific Inc.
• Luminex Corporation
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.
• QIAGEN N.V.
• Abbott Laboratories
• Siemens Healthineers
• Agilent Technologies
• bioMerieux SA
• Hoffmann-La Roche Ltd
• Eurofins Scientific SE

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

FAQs

What is the Middle East and Africa multiplexed diagnostics market forecast outlook for 2024-2032?
The Middle East and Africa multiplexed diagnostics market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 15.2% during the forecast period of 2024-2032 and is likely to reach a market value of USD 46.2 billion by 2032.

What are the major factors aiding the Middle East and Africa multiplexed diagnostics market demand?
The rising demand for innovative multiplexed assays in clinical laboratories is fuelling the demand for the market.

What are the major Middle East and Africa multiplexed diagnostics market trends?
One of the significant trends in the market is the rise in regulatory approval of advanced multiplexed tests. For instance, in February 2023, BGI Genomics’ multiplex bacterial resistance genes detection kit and multiplex nucleic acid kit for respiratory pathogens received market authorization from the Saudi Food & Drug Authority (SFDA).

What is the market segmentation based on the product type?
Based on the product type, the market is segmented into reagents, consumables, and instruments, among others.

What is the market breakup by technology?
By technology, the market is divided into low density multiplexed assays, medium density multiplexed assays, high density multiplexed assays, very high-density multiplexed assays, and next-generation sequencing assays, among others.

What are the major end users of the market?
End users of the market are hospitals, clinical laboratories, academic & research institutes, and diagnostics centers, others.

What are the applications of the multiplexed diagnostics?
Major applications of multiplexed diagnostics include disease diagnostics, drug development, and molecular diagnostics, among others.

What is the market segmentation by countries?
The market segmentation by countries includes Saudi Arabia, the United Arab Emirates, Nigeria, and South Africa, among others.

Who are the key players involved in the Middle East and Africa multiplexed diagnostics market?
The key players in the market are Thermo Fisher Scientific Inc., Luminex Corporation, Illumina, Inc., Bio-Rad Laboratories, Inc., QIAGEN N.V., Abbott Laboratories, Siemens Healthineers, Agilent Technologies, bioMerieux SA, Hoffmann-La Roche Ltd, and Eurofins Scientific SE.


This product will be delivered within 5-7 business days.